Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke. A randomized substudy of the VITATOPS trial - Dusitanond, P; Eikelboom, JW; Hankey, GJ (Stroke, 2005)
et al.